“We are excited to have Brian join us! He brings deep expertise and passion for the stem cell therapy space. He is highly respected across the field for his academic credentials, ability to bridge gaps between scientific challenges and commercial applications, and his proven track record in building biotech innovations from the ground up. With Brian’s appointment, BioLamina continues to strengthen its commitment to supporting researchers and industry partners in making the most of stem cell-based therapies and advanced cell models,” says Klaus Langhoff-Roos, CEO of BioLamina.

Brian Hawkins

Brian Hawkins brings over 20 years of combined academic and corporate experience and is widely recognized as an authority in cell therapy manufacturing, induced Pluripotent Stem Cell (iPSC) development, and cryopreservation, describes BioLamina.

He holds a PhD in Molecular Cell Biology and Biotechnology from Virginia Tech and completed his postdoctoral training at the University of Pennsylvania School of Medicine before becoming an assistant professor and founding member of the Mitochondria and Metabolism Center at the University of Washington School of Medicine.

Prior to joining BioLamina, Brian served as Chief Technology Officer at Pluristyx, where he played an important role in advancing iPSCs as a universal starting material for next generation clinical products. He has been an essential part of multiple national focus groups dedicated to progressing regenerative medicine and cell therapy, including leading the PDA/ANSI cryopreservation standard project recognized as a voluntary standard by the US FDA’s Center for Biologics Evaluation and Research (CBER). Brian continues to contribute to the field through advisory roles at the Advanced Regenerative Manufacturing Institute (ARMI), Standards Coordinating Body, and ATMP Sweden working groups.

“I look forward to working alongside the BioLamina team to form a dynamic partnership and strengthen BioLamina’s global impact. We have a unique opportunity to continue existing collaborations, foster new relationships, solve challenges, and advance the field together with peers and partners. Our shared passion for science and innovation inspires me every day,” says Brian Hawkins, CTO at BioLamina.